| Literature DB >> 21505951 |
Jana M Weiss1, Eszter Simon, Gerard J Stroomberg, Ronald de Boer, Jacob de Boer, Sander C van der Linden, Pim E G Leonards, Marja H Lamoree.
Abstract
Effect-directed analysis has been applied to a river sediment sample of concern to identify the compounds responsible for the observed effects in an in vitro (anti-)androgenicity assay. For identification after non-target analysis performed on a high-resolution LTQ-Orbitrap, we developed a de novo identification strategy including physico-chemical parameters derived from the effect-directed analysis approach. With this identification strategy, we were able to handle the immense amount of data produced by non-target accurate mass analysis. The effect-directed analysis approach, together with the identification strategy, led to the successful identification of eight androgen-disrupting compounds belonging to very diverse compound classes: an oxygenated polyaromatic hydrocarbon, organophosphates, musks, and steroids. This is one of the first studies in the field of environmental analysis dealing with the difficult task of handling the large amount of data produced from non-target analysis. The combination of bioassay activity assessment, accurate mass measurement, and the identification and confirmation strategy is a promising approach for future identification of environmental key toxicants that are not included as priority pollutants in monitoring programs.Entities:
Year: 2011 PMID: 21505951 PMCID: PMC3102845 DOI: 10.1007/s00216-011-4939-x
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
The description of the identification strategy of the active compounds present in the fractions, with the software used (method) and the limitations of each step
| Workflow | Method | Limitations | |
|---|---|---|---|
| 1. | LTQ-Orbitrap analysis of EDA identified fractions (sample = active fraction, control = non-active fraction) | LTQ-Orbitrap/Xcalibur | Electron spray ionization is a soft ionization technique and could hence exclude many compounds, matrix ion suppression |
| 2. | SIEVE procedure, aligns and base-peak frames the masses | SIEVE | No true control samples |
| 3. | Excel sheet with extracted information (peak nr, ratio between control and sample, accurate mass and retention time) | Excel | Ratio >100 between peak intensity in active and non-active fraction. Ratio <100 not tested. |
| 4. | Manual check of the peak quality (peak shape, isotopes to the molecular ion, base line elevation, etc. | Xcalibur | Time-consuming |
| 5. | Generate the chemical formula from the | Xcalibur elemental composition tool | Selected elements: N, O, C, H, F, Cl, Br, I, Si. P, S |
| 6. | NIST search of the suggested chemical formula (Observed | NIST | Limited representation of polar compounds and other less known products |
| 7. | Generate the log | EPI Suite | Theoretical values |
| 8. | Purchase and confirm analytically by retention time | LTQ-Orbitrap/Xcalibur | Lack of available standards |
| 9. | Confirm the activity in the corresponding bioassay | Bioassay | Lack of available standards |
| 10. | List of identified and confirmed active compounds to be target analyzed for concentration determination to determine the contribution to the overall activity of the sample. |
The name, CAS number, chemical formula, and the mass-to-charge ratio (m/z) as measured in the LTQ-Orbitrap (assumed to be [M + H]+) of the identified and confirmed compounds present in EDA sediment, as well as the limit of detection (LOD, μg/L) and mass tolerance (ppm) established in the sample. Androgenic and anti-androgenic potency are expressed as dihydrotestosterone (DHT) and flutamide (FLU) equivalence factors (EF), respectively, for the AR-CALUX® on a molar basis (Reference EC50/Compound EC50)
| Compound | CAS number | Molecular formula | [M + H]+ ( | LOD (μg/L) | Mass tolerance (ppm) | DHT EF | FLU EF |
|---|---|---|---|---|---|---|---|
| 7 H-Benz[ | 82-05-3 | C17H10O | 231.0806 | 20 | 0.9 | 1.4E-02 | |
| Galoxolide | 1222-05-5 | C18H26O | 259.2058 | 20 | 0.8 | 3.9E-01 | |
| Tonalide | 1506-02-1 | C18H26O | 259.2058 | <20 | 1.2 | 3.2E-01 | |
| Traseolide | 68140-48-7 | C18H26O | 259.2058 | <20 | 0.8 | 2.2E-01 | |
| Tris | 13674-84-5 | C9H18Cl3O4P | 327.0082 | <20 | 0.3 | 2.0E-04 | |
| Tris | 78-42-2 | C24H51O4P | 435.3591 | <20 | 3.0 | 1.7E-02 | |
| Nandrolone | 434-22-0 | C18H26O2 | 275.2004 | <20 | 0.7 | 1.2E-01 | |
| 5α-Androst-16-en-3-one | 18339-16-7 | C19H28O | 273.2215 | 630 | 2.2 | 1.0E-15 | 7.7E + 00 |
Fig. 1Overview of bioassay results integrating both androgenic as well as anti-androgenic activity from the reversed phase (RP) and normal phase (NP) fractions. Active (filled) and non-active (empty) fractions are indicated. These bioassay results have been reported in detail earlier [12]
The number of m/z values discriminated in the active androgenic fractions (agonistic or antagonistic and corresponding reversed phase [RP] and normal phase [NP] fractions) corresponding to identifications steps 1–10, separated into: the number of base-peak-framed m/z values from SIEVE; the number of m/z values with a ratio between 10–100 and >100 between control and sample; tentatively identified compound (some m/z values have multiple possibilities); available compounds for the confirmation steps; the analytically confirmed and the bioassay-confirmed compounds that represent the key toxicants in the sample
| Bioassay activity | Fraction | SIEVE | Ratio >100 | Tentatively identified | Available compounds | Analytical confirmed | Bioassay-confirmed |
|---|---|---|---|---|---|---|---|
| Identification step | 2 | 3–4 | 7 | 8 | 8 | 9 | |
| Agonistic | RP2NP7 | 1,002 | 38 | 25 | 8 | 2 | 1 |
| RP3NP7 | 2,915 | 62 | 7 | 1 | 0 | 0 | |
| Antagonistic | RP2NP6 | 1,206 | 35 | 6 | 2 | 1 | 1 |
| RP3NP2 | 3,309 | 26 | 2 | 0 | 0 | 0 | |
| RP3NP5 | 1,141 | 42 | 42 | 7 | 5 | 4 | |
| RP3NP6 | 2,940 | 26 | 4 | 2 | 1 | 1 | |
| RP4NP2 | 291 | 1 | 1 | 0 | 0 | 0 | |
| RP4NP7 | 2,003 | 29 | 8 | 2 | 1 | 1 | |
| Total | 14,807 | 259 | 95 | 22 | 10 | 8 | |